[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@PeptidreamInc PeptiDream Inc.PeptiDream Inc. posts on X about $4587t, kyoto, $7747t, $2502t the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Social category influence travel destinations XXXX% stocks XXXX% countries XXXX%
Social topic influence $4587t #1, kyoto 9.09%, $7747t 9.09%, $2502t 9.09%, $3407t 9.09%, fda 9.09%, $alxn 9.09%, discovered 9.09%, japan XXXX%
Top accounts mentioned or mentioned by @citeline @alexionpharma
Top posts by engagements in the last XX hours
"📢 We will participate in the 65th Annual Meeting of the Japanese Society of Nuclear Medicine (Nov 13-15 Kyoto) PD/PDR will host lectures academic presentations and seminars 👉 Learn more: #NuclearMedicine #Kyoto"
X Link 2025-11-07T07:11Z XX followers, XXX engagements
"We are excited to announce the nomination of a clinical development candidate from our collaboration with Asahi Kasei Pharma We look forward to further progress in the program and the advancement of the candidate into clinical development"
X Link 2025-12-10T07:32Z XX followers, XX engagements
"📢We've submitted INDs to the US FDA for Phase X trials of 225Ac-PD-32766 (radiotherapeutic) & 64Cu-PD-32766 (radiodiagnostic) in Clear Cell Renal Cell Carcinoma. Details: #Radiopharmaceuticals #KidneyCancer #CAIX #CA9 #PeptideTherapeutics #Macrocycles"
X Link 2025-11-25T07:26Z XX followers, XXX engagements
"Excited to share that Alexion AstraZeneca Rare Disease (@AlexionPharma) has started a Phase X trial of ALXN2420 for adults with Acromegaly originally discovered at PeptiDream. Details:"
X Link 2025-11-27T09:25Z XX followers, XXX engagements
"R&D Day archive & decks are now available. Explore our R&D strategy pipeline updates and milestones. Video: Presentation material:"
X Link 2025-12-09T11:19Z XX followers, XXX engagements
"We are pleased to announce the approval of a Phase X clinical research for 64Cu-PD-29875 (targeting Claudin 18.2) in gastric cancer patients at the National Cancer Center Japan. jRCT Link: #Radiopharmaceuticals #Radioligandtherapy"
X Link 2025-12-11T07:22Z XX followers, XX engagements